Androgenetic alopecia Androgenetic alopecia, Polynucleotides, Hair loss, Hair thinning, Hair regrowth, VEGF, angiogenesis.
Conditions
Interventions
Polynucleotides injectable
Experimental Drug
Rejuran classic
Sponsors
Rejuran
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.AGA Hamilton-Norwood Stages III to V (including Type III vertex) were enrolled. Subjects must maintain the normal hair length, color and style during the study. 2.Female pattern hair loss Ludwig type I-II
Exclusion criteria
Exclusion criteria: 1. Patients who are not interested or deny about this study. 2. Patient who is undertaking treatment for disease before this study periods: 2.1 Treatment with topical medication within 6 months 2.2 Treatment with systemic medication (Finasteride within 12 months,Minoxidil within 12 months, Dutasteride within 18 months) 2.3 Using shampoo for hair growth stimulation (non- medicated) treatment or taking hair supplements within 3 months. 2.4Treatment with oral supplement within 12 months 2.5 Using shampoo for hair growth stimulation (non- medicated) treatment or taking hair supplements within 3 months 2.6 Any other treatment for hair growth within 1 month. 3. Patient with alopecia other than androgenetic alopecia 4. Patient with other systemic disease like malnutrition, autoimmune disease, symptomatically immunocompromised disease like HIV, syphilis and cancer. 5. Patient with lack of cooperation as well as psychological disorder. 6. Patient with history of hair transplantation or restoration surgery. 7. Patient who is unreliable or poor compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hair density, hair diameter every 1 month, for 4 months dermoscope,photograph | — |
Secondary
| Measure | Time frame |
|---|---|
| satisfaction every 1 month,for 4 months 7 point improvement scale | — |
Countries
Thailand
Contacts
Public ContactJitlada Meephansan
Thammasat university
Outcome results
None listed